Evidence map›Paper›PMID 41256793›Full record

ArticleFrontiers in cellular and infection microbiology2025

Weixiao Zhang, Bingxin Liu, Sai Wang, Xinlong Xu, Qiwang Jin, Chen Yang, Hui Wang, Erhe Gao, Bin Zhan, Shili Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weixiao Zhang *First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Bingxin Liu *Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
Sai WangFirst Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Xinlong XuAnhui Key Laboratory of Infection and Immunity of Bengbu Medical University, Bengbu, China.
Qiwang JinAnhui Key Laboratory of Infection and Immunity of Bengbu Medical University, Bengbu, China.
Chen YangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical University, Bengbu, China.
Hui WangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical University, Bengbu, China.
Erhe GaoLewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Bin ZhanNational School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
Shili WuFirst Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Rui WangScientific Research Center, Bengbu Medical University, Anhui, Bengbu, China.
Rui ZhouFirst Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Xiaodi YangAnhui Key Laboratory of Infection and Immunity of Bengbu Medical University, Bengbu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Myocardial infarction (MI) is a severe cardiovascular condition arising from a sudden reduction or complete cessation of blood supply via the coronary arteries, resulting in localized necrosis of the corresponding myocardial tissue due to persistent ischemia and hypoxia. It is a life-threatening cardiovascular disease with high death rate and poor prognosis due to myocardial necrosis. Results: Our study in a MI mouse model demonstrated that treatment with r Conclusions: These findings reveal that r

Indexed as

Antigens, HelminthEchinococcus granulosusMacrophagesMyocardial InfarctionAnimalsArginaseCytokinesDisease Models, AnimalEchinococcosisInflammationLipoproteinsMacrophage ActivationMaleMiceMice, Inbred C57BLNitric Oxide Synthase Type IIantigen B, Echinococcus granulosusAntigens, HelminthArg1 protein, mouseArginaseCytokinesLipoproteinsNitric Oxide Synthase Type IINLR Family, Pyrin Domain-Containing 3 Proteinantigen B (EgAgB)Echinococcus granulosusmacrophagemyocardial infarctionNOD-like receptor family pyrin domain-containing 3 (NLRP3)

Identifiers

PMID41256793
PMCPMC12620417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.